Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYLANASDAQ:CRTXNASDAQ:CYTHNASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ACRTXCortexyme$1.17$1.07$1.78▼$40.66$35.28M1.4620,672 shs81,520 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57504,272 shsN/AINKTMiNK Therapeutics$7.34+2.5%$7.48$4.56▼$13.79$29.26M0.1512,138 shs1,499 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRTXCortexyme0.00%+12.50%+14.71%-18.75%+48.10%CYTHCyclo Therapeutics0.00%0.00%0.00%+6.44%-42.81%INKTMiNK Therapeutics+0.11%+1.30%+3.39%-6.94%-24.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINKTMiNK Therapeutics2.7278 of 5 stars3.54.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala Pharmaceuticals 0.00N/AN/AN/ACRTXCortexyme 0.00N/AN/AN/ACYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideINKTMiNK Therapeutics 3.00Buy$37.50410.90% UpsideCurrent Analyst Ratings BreakdownLatest AYLA, INKT, CRTX, and CYTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ACYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43INKTMiNK TherapeuticsN/AN/AN/AN/A($5.23) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ACRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ACYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/AINKTMiNK Therapeutics-$22.46M-$2.52N/AN/AN/AN/AN/A-189.14%8/12/2025 (Estimated)Latest AYLA, INKT, CRTX, and CYTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A3/18/2025Q4 2024INKTMiNK Therapeutics-$0.50-$0.62-$0.12-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28CRTXCortexymeN/A9.929.92CYTHCyclo TherapeuticsN/A0.170.16INKTMiNK TherapeuticsN/A0.890.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%CRTXCortexyme63.18%CYTHCyclo Therapeutics68.55%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%CRTXCortexyme27.90%CYTHCyclo Therapeutics29.78%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataINKTMiNK Therapeutics303.99 million3.15 millionNo DataAYLA, INKT, CRTX, and CYTH HeadlinesRecent News About These CompaniesMiNK Therapeutics Announces Virtual Annual Shareholders MeetingJune 10 at 1:33 PM | globenewswire.comMiNK Therapeutics (NASDAQ:INKT) Shares Up 0.1% - Still a Buy?June 10 at 2:11 AM | americanbankingnews.comMiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease TreatmentJune 4, 2025 | nasdaq.comMiNK Therapeutics ontvangt NIH-subsidie voor GvHD-therapieJune 2, 2025 | nl.investing.comMiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant PatientsJune 2, 2025 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comQ1 2025 Mink Therapeutics Inc Earnings CallMay 16, 2025 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 16, 2025 | finance.yahoo.comMiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programsMay 15, 2025 | msn.comMiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic ProgressMay 15, 2025 | globenewswire.comA Look at MiNK Therapeutics's Upcoming Earnings ReportMay 14, 2025 | benzinga.comMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportMay 5, 2025 | globenewswire.comEarnings call transcript: Mink Therapeutics Q4 2024 reports reduced net lossMarch 20, 2025 | uk.investing.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comMiNK Therapeutics reports Q4 EPS (62c), consensus (50c)March 19, 2025 | markets.businessinsider.comQ4 2024 Mink Therapeutics Inc Earnings CallMarch 19, 2025 | finance.yahoo.comMink Therapeutics rapporteert lager nettoverlies in Q4 2024March 18, 2025 | nl.investing.comMiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comMiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business ProgressMarch 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYLA, INKT, CRTX, and CYTH Company DescriptionsAyala Pharmaceuticals NASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Cortexyme NASDAQ:CRTX$1.17 0.00 (0.00%) As of 06/9/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.MiNK Therapeutics NASDAQ:INKT$7.34 +0.18 (+2.51%) Closing price 03:58 PM EasternExtended Trading$7.18 -0.17 (-2.25%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
